StockNews.AI
PCRX
StockNews.AI
210 days

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX

1. A class action lawsuit has been filed against Pacira Biosciences. 2. The lawsuit involves allegations of securities fraud against the company. 3. Pacira's stock previously dropped 47.67% after a patent was invalidated. 4. Investors can join the class until March 14, 2025. 5. Pomerantz LLP specializes in securities class action litigation.

4m saved
Insight
Article

FAQ

Why Bearish?

The lawsuit adds uncertainty, similar to past litigation that harmed stock prices.

How important is it?

The ongoing class action may influence investor sentiment and stock performance.

Why Short Term?

Immediate market reaction to lawsuits typically affects prices quickly.

Related Companies

PCRX
NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Pacira and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until March 14, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you are a shareholder who purchased or otherwise acquired Pacira securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. [Click here for information about joining the class action] Pacira Biosciences, Inc. (PCRX) ("Pacira" or the "Company") for potential violations of the federal securities laws. On August 9, 2024, Pacira announced that the U.S. District Court for the District of New Jersey, in a patent infringement lawsuit against eVenus Pharmaceutical Laboratories, Inc., had invalidated Pacira's '495 patent, covering its Exparel non-opioid pain treatment, on the basis of obviousness and anticipation. On this news, Pacira's stock price fell $10.66 per share, or 47.67%, to close at $11.70 per share on August 9, 2024. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP

Related News